Clinical trial
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of…
NCT00111839 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00111839 |
|---|---|
| Title | Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer |
| Official title | Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a… |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Pemetrexed, Matuzumab |
| Enrollment | 150 |
| Start date | May 31, 2005 |
| Primary completion | Jul 31, 2007 |
| Completion | Mar 31, 2009 |
| First posted | May 27, 2005 |
| Last update posted | Apr 6, 2018 |
| Countries | Austria, Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: